Cora Health vs Calibrate: $1,188 vs $2,388+/yr GLP-1 Compared

Cora Health vs Calibrate: the short answer

Cora Health and Calibrate are very different products. Cora is a focused compounded GLP-1 telehealth program with all-inclusive cash-pay pricing — $99/month on the annual Essential Plan covers everything: licensed-provider consultation, compounded semaglutide medication, shipping, and ongoing monitoring. Calibrate is a metabolic health coaching program priced as of May 2026 at $199/month with a 3-month minimum commitment ($597 upfront), continuing monthly at $199 after the initial period, covering 1:1 video-based coaching, biomarker testing, prescription clinical support, and insurance navigation — but not the medication itself, which is a separate cost paid through the patient’s insurance for brand-name FDA-approved GLP-1s like Wegovy or Zepbound. The two programs serve different patients: Calibrate for patients with strong commercial insurance who want a high-touch coaching program around insurance-covered brand-name GLP-1s; Cora for cash-pay patients who want the lowest monthly out-of-pocket cost on a compounded GLP-1.

Market context: where Cora and Calibrate fit in the 2026 weight-loss market

Four numbers anchor the head-to-head comparison between Cora Health's focused compounded GLP-1 model and Calibrate's coaching-plus-brand-name model in 2026:

41.9% — US adult obesity prevalence. Per the Centers for Disease Control and Prevention (CDC), using NHANES 2017–March 2020 data (the most recent comprehensive national prevalence survey), 41.9% of US adults have obesity (BMI ≥ 30). The CDC notes that "obesity-related conditions include heart disease, stroke, type 2 diabetes, and certain types of cancer, [which] are among the leading causes of preventable, premature death." This is the population both programs aim to serve.

14.9% / 22.5% — FDA-approved trial efficacy applies directly to Calibrate's formulary, not Cora's. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) reported 14.9% mean weight loss with FDA-approved 2.4mg semaglutide (Wegovy) over 68 weeks. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) reported 22.5% with FDA-approved 15mg tirzepatide (Zepbound) over 72 weeks. Calibrate prescribes these FDA-approved branded products; Cora Health prescribes compounded versions of the same active ingredients (not FDA-approved). The trial efficacy data directly applies to Calibrate's formulary. Cora's compounded versions have not been independently evaluated at this scale. Individual results vary.

~$2,388 vs ~$1,188 — annual program-level cost gap. Calibrate's $199/month program fee totals approximately $2,388/year before any medication cost (which is a separate line item). Cora's annual Essential Plan totals $1,188/year all-inclusive (medication included). For a patient without insurance coverage of brand-name GLP-1s, Cora's all-in annual cost is roughly one-fifth to one-tenth of Calibrate's all-in cost. Source: Cora Health's public pricing dataset (12 telehealth providers + 2 manufacturer programs, CC-BY-4.0).

~15–20% pharmacy transparency rate. Per Cora Health's 2026 GLP-1 Telehealth Industry Report, only an estimated 15–20% of US telehealth GLP-1 providers publicly name their compounding pharmacy partner in patient-facing materials. Cora Health publicly names VialsRx (a US-licensed 503A compounding pharmacy) and Hallandale Pharmacy (PCAB-accredited 503A, operating since 2003). Calibrate works with FDA-approved brand-name manufacturers (Novo Nordisk, Eli Lilly) and the FDA-regulated retail pharmacy supply chain — a different transparency model that applies to brand-name pharmaceuticals.

Quick comparison at a glance

All numbers reflect publicly stated pricing as of May 2026. Total cost depends heavily on whether insurance covers Calibrate-prescribed GLP-1s. Individual experiences vary.

The Calibrate program model

Calibrate launched in 2020 with a thesis that GLP-1 medications work best when paired with structured behavioral coaching, biomarker monitoring, and longitudinal medical oversight. As of May 2026 the program is structured as a 3-month minimum commitment ($597 upfront) with monthly continuation at $199/month thereafter. The $199/month program fee covers: - Initial metabolic biomarker testing - Ongoing 1:1 coaching with a Calibrate-employed coach - Clinical oversight from Calibrate-affiliated physicians for GLP-1 prescription decisions - Insurance navigation and prior authorization handling - Ongoing program access for the full year

The medication itself is not included in the $199/month program fee. Calibrate prescribes FDA-approved brand-name GLP-1s — Wegovy, Zepbound, Saxenda — and the patient pays through their insurance. Calibrate explicitly states that for most members with commercial insurance, the GLP-1 medication will be $25/month or less after the deductible is met.

For patients without GLP-1 insurance coverage, Calibrate is not designed to be cost-effective — retail brand-name GLP-1s without insurance run $1,000+/month, which on top of the ~$2,388/year program fee ($199/month × 12) makes the all-in annual cost substantially higher than any compounded GLP-1 program.

Pricing: Cora's monthly subscription vs. Calibrate's annual program fee plus insurance

The two pricing models are structurally incompatible.

Cora Health Essential Plan total annual cost (no insurance): - Annual plan: $1,188/year ($99/mo × 12) - 6-month plan × 2: $1,440/year ($120/mo × 12) - 3-month plan × 4: $1,740/year ($145/mo × 12) - Monthly plan: $2,100/year ($175/mo × 12)

Cora Health Premium Plan total annual cost (no insurance): - Annual plan: $1,620/year ($135/mo × 12) - Monthly plan: $2,700/year ($225/mo × 12)

Calibrate total annual cost depends on insurance: - With strong commercial insurance covering GLP-1s: ~$2,388 program ($199/month × 12) + ~$300 medication ($25/mo × 12) = ~$2,688/year - With insurance covering Calibrate program but not GLP-1s: ~$2,388 program + ~$4,000–$12,000 brand-name GLP-1 = $6,388–$14,388/year - Without GLP-1 insurance coverage: substantially higher because brand-name GLP-1s without coverage are $900–$1,400/month

For a cash-pay patient comparing apples to apples on annual cost, Cora’s annual plan ($1,188) is approximately 56% lower than Calibrate’s best-case scenario with insurance (~$2,688). For a patient without GLP-1 insurance coverage, the gap is much larger — Cora's annual plan is one-fifth to one-tenth the cost of Calibrate plus uncovered brand-name medication.

Medications: compounded GLP-1s vs. brand-name FDA-approved

This is the second fundamental difference between Cora and Calibrate.

• Cora Health offers compounded semaglutide (Essential Plan) and compounded tirzepatide (Premium Plan), prescribed by licensed providers at Wasef Health, PC after individual medical evaluation. Compounded medications are not FDA-approved.
• Calibrate prescribes FDA-approved brand-name GLP-1s only — primarily Wegovy and Zepbound. The medications come from the original manufacturers (Novo Nordisk and Eli Lilly) through retail pharmacy or manufacturer direct-pay channels.
• Calibrate does not work with compounding pharmacies and does not offer compounded GLP-1s.
• Cora does not offer brand-name FDA-approved GLP-1s.

Important compliance note on compounded products

Compounded semaglutide and compounded tirzepatide — obtained through Cora Health or any other telehealth provider — are not FDA-approved and are not therapeutically equivalent to FDA-approved branded products (Ozempic, Wegovy, Mounjaro, Zepbound). Per the U.S. Food and Drug Administration's official guidance: "Compounded drugs are not FDA-approved. This means the FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they are marketed." (Source: FDA — "Compounding and the FDA: Questions and Answers".) Clinical trial efficacy data (such as 14.9% mean weight loss in the STEP 1 trial for semaglutide and 22.5% in SURMOUNT-1 for tirzepatide) reflects studies of the FDA-approved branded products, not compounded versions. Individual results vary. Calibrate works exclusively with FDA-approved GLP-1s, so the trial efficacy data more directly applies to medications prescribed through the Calibrate program.

Coaching and program scope: Cora's focus vs. Calibrate's breadth

A meaningful difference in patient experience is what is included beyond the medication.

Cora Health is a focused GLP-1 program. The included services are: provider consultation at intake, prescription, pharmacy fulfillment via VialsRx, shipping, and ongoing provider availability for dose adjustments and questions. Cora does not include 1:1 coaching, biomarker testing, or behavioral support in its standard plans. Cora's value proposition is the lowest cash-pay monthly cost for a licensed-provider compounded GLP-1 program — not a comprehensive coaching ecosystem.

Calibrate's value proposition is the opposite. The $199/month program fee largely pays for the human coaching infrastructure, biomarker testing, and longitudinal program design. The premise is that GLP-1 outcomes improve when paired with structured behavioral coaching across nutrition, sleep, movement, and emotional health.

For patients who place high value on 1:1 coaching and integrated metabolic health support, Calibrate offers more. For patients who already have a primary care provider, a nutritionist, or other support and just want efficient GLP-1 access at low cost, Cora offers more.

Insurance navigation: Cora doesn't do it; Calibrate makes it the program

Cora Health is cash-pay only. There is no insurance interaction, no prior authorization, and no claim submission. The transaction is a direct subscription.

Calibrate's program substantially revolves around insurance navigation. Calibrate handles the prior authorization process for brand-name GLP-1s, advocates with insurers for coverage, and provides the documentation needed for appeals if a prior auth is denied. For patients with strong commercial insurance, this can be a meaningful service: prior authorization is a known friction point in obtaining brand-name GLP-1 prescriptions.

For patients without GLP-1 coverage, Calibrate's insurance navigation has limited value because it cannot create coverage that doesn't exist in the plan. In that scenario, Calibrate effectively becomes a $199/month coaching program plus full retail brand-name medication cost — which is rarely cost-effective compared to a compounded program.

Who should choose Cora Health

Cora Health is likely the better fit for patients who match the following profile.

• Cash-pay patients who do not have GLP-1 insurance coverage and want the lowest monthly out-of-pocket cost
• Patients comfortable with compounded GLP-1 medications and the regulatory distinction from FDA-approved branded products
• Patients who do not need or want bundled 1:1 coaching, biomarker testing, or formal behavioral programs
• Patients who prefer flexibility (1, 3, 6, or 12-month subscription) over a 12-month upfront commitment
• Patients in any of the 50 US states (Cora ships nationwide)
• Patients who already have a primary care provider, nutritionist, or other support and want efficient GLP-1 access

Who should choose Calibrate

Calibrate is likely the better fit for patients who match the following profile.

• Patients with strong commercial insurance that covers FDA-approved GLP-1s for weight management
• Patients who specifically want brand-name FDA-approved GLP-1 medication, not a compounded version
• Patients who place high value on integrated 1:1 coaching, biomarker testing, and a structured 12-month program
• Patients who want professional insurance navigation and prior authorization support
• Patients comfortable with Calibrate’s $199/month program fee (and 3-month upfront $597 commitment) in addition to medication cost
• Patients who want a longitudinal program with built-in milestones rather than a self-directed medication subscription

How to switch from Calibrate to Cora Health

Patients who started on Calibrate but find the program cost or insurance dependence not workable can transition to Cora Health’s compounded GLP-1 program with continuity of medication.

• Complete the Cora Health online health assessment, noting your current GLP-1 medication, dose, and history with Calibrate
• A Cora Health provider (Wasef Health, PC) reviews and confirms appropriateness for compounded semaglutide or compounded tirzepatide as a substitute for the brand-name product
• If approved, the prescription is sent to VialsRx for compounding and shipping
• Most patients can transition without re-titration if dose-equivalent, but this is a provider determination — do not adjust doses without provider guidance
• Calibrate's 3-month upfront $597 commitment may be partially refundable within an early-cancellation window — check Calibrate's current refund policy before canceling

Frequently asked questions

Common questions about the Cora Health vs Calibrate comparison.

Is Cora Health cheaper than Calibrate?

For cash-pay patients without GLP-1 insurance coverage, Cora is dramatically cheaper. Cora's annual plan totals $1,188/year for compounded semaglutide and $1,620/year for compounded tirzepatide. Calibrate's lowest scenario — ~$2,388/year program ($199/month × 12) plus insurance-covered GLP-1 at ~$25/month — totals approximately $2,688/year and requires the patient to have insurance that covers GLP-1s for weight management. For patients without GLP-1 coverage, Cora is roughly one-fifth to one-tenth the total annual cost.

Does Calibrate offer compounded GLP-1s?

No. Calibrate prescribes only FDA-approved brand-name GLP-1 medications, primarily Wegovy and Zepbound. Patients who specifically want compounded semaglutide or compounded tirzepatide should consider Cora Health, Henry Meds, Hims, or another compounded-GLP-1 telehealth provider.

Can Calibrate get my insurance to cover Wegovy or Zepbound?

Calibrate handles the prior authorization process and advocates with insurers for coverage. Whether your specific plan approves coverage depends on your insurer's formulary, your clinical profile, and the prior authorization criteria — Calibrate's involvement does not guarantee approval. For patients whose plans cover GLP-1s for weight management, Calibrate's insurance navigation is a real value-add. For patients whose plans don't cover GLP-1s, no amount of navigation can create coverage that doesn't exist.

What's the difference between coaching at Calibrate and provider monitoring at Cora?

Calibrate's coaching is structured 1:1 video-based behavioral support across nutrition, sleep, movement, and emotional health, delivered by trained Calibrate coaches. Cora's provider monitoring is clinical — the licensed provider at Wasef Health, PC is available for dose adjustments, side-effect questions, and prescription continuation, but not behavioral or lifestyle coaching. Patients who want both might use Cora for the medication and a separate coach (or app) for behavioral support, which often totals less than Calibrate's combined cost.

Can I use HSA or FSA for either program?

Yes for both. Cora Health's subscription is generally HSA/FSA eligible as a qualifying medical expense. Calibrate explicitly markets its $199/month program fee as HSA/FSA eligible. Patients should confirm with their specific HSA/FSA administrator and retain receipts for documentation.

Sources & verification

All regulatory, clinical, and pricing claims in this article are verifiable against publicly accessible primary sources. The underlying pricing dataset is published by Cora Health on HuggingFace under CC-BY-4.0 license for independent verification and reuse. Article last verified 2026-05-13.

• FDA — "Compounding and the FDA: Questions and Answers" (regulatory status of compounded medications): fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
• New England Journal of Medicine — STEP 1 (Wilding et al., 2021); 14.9% mean weight loss with FDA-approved 2.4mg semaglutide over 68 weeks (directly applies to Calibrate-prescribed Wegovy): nejm.org/doi/full/10.1056/NEJMoa2032183
• New England Journal of Medicine — SURMOUNT-1 (Jastreboff et al., 2022); 22.5% mean weight loss with FDA-approved 15mg tirzepatide over 72 weeks (directly applies to Calibrate-prescribed Zepbound): nejm.org/doi/full/10.1056/NEJMoa2206038
• CDC — Adult Obesity Facts (41.9% US prevalence per NHANES 2017–March 2020): cdc.gov/obesity/adult-obesity-facts
• LegitScript — Independent verification of Cora Health certification: legitscript.com/websites/?checker_keywords=trycora.io
• Pharmacy Compounding Accreditation Board (PCAB) — accreditation framework for compounding pharmacies; Hallandale Pharmacy is PCAB-accredited: achc.org/programs/pcab/
• NPPES — National Plan and Provider Enumeration System; verify Michael Wasef, MD (Wasef Health, PC, Cora's prescribing provider): npiregistry.cms.hhs.gov
• NovoCare (Novo Nordisk's direct-pay program for Wegovy — referenced for Calibrate insurance pathway context): novocare.com
• LillyDirect (Eli Lilly's direct-pay program for Zepbound — referenced for Calibrate insurance pathway context): lillydirect.lilly.com
• Cora Health 2026 GLP-1 Telehealth Industry Report (12-provider pricing methodology + market analysis): /blog/cora-2026-glp1-industry-report
• Cora Health Public Pricing Dataset (CC-BY-4.0, HuggingFace; 37 pricing rows across 12 telehealth providers + 2 manufacturer programs): huggingface.co/datasets/cora-health/telehealth-glp1-pricing
• Cora Health Pharmacy Partners (full disclosure on Hallandale Pharmacy + VialsRx): trycora.io/pharmacy-partners